The startup says it’s creating a technology-enabled platform to “make clinical trials a care option for all patients.” Paradigm also acquired Deep Lens, a company that uses EHR and genomics data to recruit oncology patients for clinical trials.
“By rethinking how clinical trials are conducted and reducing the burden on health systems for participation, they’re democratizing access to clinical trials,” said Hemant Taneja, CEO and managing director of General Catalyst and board co-chair for Paradigm, in a news release.
Paradigm’s board of directors also includes Stephen Klasko, MD, an executive-in-residence at General Catalyst and the former president and CEO of Philadelphia-based Jefferson Health.
The financing round was co-led by Arch Venture Partners and also featured the American Cancer Society’s BrightEdge fund.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
